Skip to main content
OpenTrials
Completed

NCT Number: NCT02899455

Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

23 institutions including Samsung Medical Center

Seoul, South Korea

About this study

This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 19 ≤ age ≤ 75
  • at Visit 1 1) BP: sitDBP ≥ 90mmHg 2) Cholesterol : LDL-C ≤ 250mg/dL, TG < 400mg/dL
  • at Visit 2 : after TLC (after 4weeks) 1) BP: 80 mmHg ≤ sitDBP < 110mmHg 2) Cholesterol : following risk category (Cardiovascular Risk category) A : CHD risk factor 0 - 1, 160mg/dL ≤ LDL-C ≤ 250mg/dL B①: CHD risk factor≥2 and 10 year risk <10%, 160mg/dL ≤ LDL-C ≤ 250mg/dL B②: CHD risk factor≥2 and 10 year risk =10-20%, 130mg/dL ≤ LDL-C ≤ 250mg/dL C : CHD/CHD risk equivalents* or 10 year risk>20 ,100mg/dL ≤ LDL-C ≤ 250mg/dL 3) TG < 400mg/dL 4. Patients understood the contents and purpose of this trial and signed informed consent form

Exclusion criteria

  • At Visit 1, BP difference SBP ≥20mmHg or DBP ≥10mmHg
  • Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA. reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy
  • Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin
  • CPK normal range ≥ 3times
  • Uncontrolled primary hypothyroidism(TSH normal range ≥ 2 times)
  • Renal disease or suspected renal disease (Scr ≥ 2mg/dL, AST or ALT≥2 times)
  • Active gout or hyperuricemia(at Visit 1, uric acid > 9mg/dL)
  • IDDM or uncontrolled diabetes mellitus (HbA1c>9%)
  • ventricular arrhythmia
  • medical history
  • severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertension
  • encephalopathy, transient cerebral ischemic attack(TIA)
  • severe heart disease(heart failure of NYHA class III-IV), valvular disease of heart or myocardial infarction and unstable angina
  • angioplasty or coronary artery bypass graft(CABG) surgery within 6months

Treatment and study plan

HGP0904

Drug

HGP0608

Drug

HGP0816

Drug

HGP0904 Placebo

Drug

HGP0816 Placebo

Drug

Primary outcomes

  1. Percentage change from baseline in LDL-cholesterol at Week 8

    Time frame: baseline and 8 weeks

  2. Change from baseline in sitDBP at Week 8

    Time frame: baseline and 8 weeks

Secondary outcomes

  1. Percentage change from baseline in LDL cholesterol at Week 4

    Time frame: baseline and 4 weeks

  2. Percentage change from baseline in Total cholesterol, HDL cholesterol, Triglyceride at Week 4,8

    Time frame: baseline, 4weeks and 8 weeks

  3. Change from baseline in sitDBP at Week 4

    Time frame: baseline and 4weeks

  4. Change from baseline in sitSBP at week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

  5. Proportion of subjects achieving LDL-cholesterol goals by cardiovascular risk category at Week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

  6. Proportion of subjects achieving Blood Pressure control by cardiovascular risk category at Week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

  7. Proportion of subjects achieving LDL-cholesterol goals and Blood Pressure control by cardiovascular risk category at Week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

Sponsors and collaborators

Lead sponsor

Hanmi Pharmaceutical Company Limited

Industry

Registry information

Official study title

Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Sep 14, 2016
Registry last updated
Oct 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.